Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.39 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CD38 | P28907 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12313392 | 0.87 | TAAR1 (0.43) | SLC6A2SLC6A4TAAR1HSD11B1SMN1; SMN2 | |
| SCHEMBL12157171 | 0.84 | SLC6A2 (0.42) | SLC6A2SLC6A4STIM1ORAI1TAAR1 | |
| Bromide SCHEMBL25372266 | 0.82 | SLC6A2 (0.40) | SLC6A2SLC6A4STIM1ORAI1TAAR1 | |
| SCHEMBL19303142 | 0.81 | HSD11B1 (0.41) | SLC6A2SLC6A4STIM1ORAI1TAAR1 | |
| SCHEMBL19728344 | 0.80 | SLC6A2 (0.42) | SLC6A2SLC6A4STIM1ORAI1TAAR1 | |
| SCHEMBL19055379 | 0.80 | SLC6A2 (0.39) | SLC6A2SLC6A4STIM1ORAI1TAAR1 | |
| SCHEMBL91337 | 0.79 | KDM4E (0.45) | TAAR1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL145819 | 0.79 | SLC6A2 (0.40) | SLC6A2SLC6A4STIM1ORAI1TAAR1 | |
| SCHEMBL13856265 | 0.79 | TAAR1 (0.39) | TAAR1HSD11B1SMN1; SMN2KDM4EP2RX7 | |
| SCHEMBL2776951 | 0.79 | STIM1 (0.42) | SLC6A2SLC6A4STIM1ORAI1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109761911-A | A kind of preparation method of the polysubstituted pyrimidine derivative as Elagolix intermediate | 安徽诺全药业有限公司 | 2019-05-17 | — | — | CN | claimed |
| WO-2023230543-A1 | INDOLIZINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023230540-A2 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023230542-A2 | PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023147597-A2 | ALLOSTERIC STING MODULATORS AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230151007-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151007-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-05-18 | — | — | US | disclosed |
| EP-3636636-B1 | PYRIDONE COMPOUND AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE | MITSUI CHEMICALS AGRO INC (JP) | 2022-07-06 | — | — | EP | disclosed |
| EP-3444238-B1 | PROCESS FOR PREPARING DIFLUOROMETHYLENE COMPOUNDS | SATO PHARMA (JP) | 2021-12-08 | — | — | EP | disclosed |
| US-7402674-B2 | 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH, (DE) | 2008-07-22 | — | — | US | disclosed |
| WO-2008066356-A1 | ARYL COMPOUNDS AS PPAR LIGANDS AND THEIR USE | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2008-06-05 | — | — | WO | disclosed |
| US-20080004287-A1 | Substituted Piperidines that Increase P53 Activity and the Uses Thereof | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
| WO-2007145922-A2 | BENZAZEPINONES AS SODIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-7291730-B2 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-11-06 | — | — | US | disclosed |
| US-7271270-B2 | High affinity small molecule C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-20050107609-A1 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY | 2005-05-19 | — | — | US | disclosed |
| US-6838463-B2 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-01-04 | — | — | US | disclosed |
| EP-1366026-B1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040077669-A1 | Pyrimidine compounds and their use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004287-A1 | Substituted Piperidines that Increase P53 Activity and the Uses Thereof | TP53, MDM2, TP53BP1 | SLC6A2 4851/4885SLC6A4 4787/4885STIM1 881/4885 |
| US-20050107609-A1 | Pyrimidine compounds and their use | TYMP, TYMS, UMPS | SLC6A2 3899/4885SLC6A4 2558/4885STIM1 4287/4885 |
| US-20040077669-A1 | Pyrimidine compounds and their use | TYMP, TYMS, DPYD | SLC6A2 3998/4885SLC6A4 2339/4885STIM1 4173/4885 |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | KRAS, NRAS, TP53 | SLC6A2 4805/4885SLC6A4 4659/4885STIM1 3091/4885 |
| US-20230151007-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | SLC6A2 4861/4885SLC6A4 4847/4885STIM1 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.